Skip to main content
Clinical Trials/CTRI/2019/05/019304
CTRI/2019/05/019304
Not yet recruiting
Phase 2

Comparative evaluation of combined treatment using 0.03% chloroquine phosphate and 0.1% olopatadine eye drops with monotherapy using 0.1% olopatadine eye drops in patients with allergic conjunctivitis

RP Centre0 sites0 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Health Condition 1: H101- Acute atopic conjunctivitis
Sponsor
RP Centre
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
RP Centre

Eligibility Criteria

Inclusion Criteria

  • All patients attending the outpatient department with clinically diagnosed allergic eye disease based on signs (itching, watering) and symptoms (conjunctival hyperemia, palpebral hypertrophy) will participate in the study. No other methods of diagnosis will be considered besides clinical signs and symptoms.

Exclusion Criteria

  • 1\.Uveitis, conjunctivitis and other ocular pathologies
  • 2\.Bronchial asthma, eczema
  • 3\.History of dry eye, blepharitis, contact lens use
  • 4\.Receiving topical or systemic medications
  • 5\.History of sensitivity to any constituents of the eye drops

Outcomes

Primary Outcomes

Not specified

Similar Trials